论文部分内容阅读
目的分析乳腺癌组织中蛋白激酶B(AKT)、P53及人类表皮生长因子受体-2(Her-2)表达水平与新辅助化疗疗效及预后的相关性。方法收集2012年4月-2014年5月来该院乳腺外科就诊的乳腺癌确诊患者150例。所有患者均给予乳腺癌切除术和术后新辅助化疗治疗,乳腺病理组织检查判断患者AKT、P53及Her-2表达水平,并以此分为阳性表达组和阴性表达组,通过术后随访观察2组患者治疗效果及预后情况差异,判断其相关性。结果AKT阳性组治疗有效率低于AKT阴性组,预后不佳比率大于AKT阴性组;P53阳性表达组治疗有效率小于P53阴性组,预后不佳比率大于P53阴性组;Her-2阳性表达组治疗有效率高于Her-2阴性表达组,预后不佳例数占比低于Her-2阴性表达组,差异均有统计学意义(P<0.05)。结论 AKT和P53阳性表达与乳腺癌患者新辅助化疗效果和预后呈负相关,而Her-2阳性表达率与乳腺癌患者新辅助化疗效果和预后呈正相关。
Objective To analyze the correlation between the expression of protein kinase B (AKT), P53 and Her-2 in breast cancer and the efficacy and prognosis of neoadjuvant chemotherapy. Methods A total of 150 cases of breast cancer diagnosed in breast surgery from April 2012 to May 2014 were collected. All patients were treated with excision of breast cancer and neoadjuvant chemotherapy after operation. The expression of AKT, P53 and Her-2 in breast cancer tissues were determined by histopathological examination, and divided into positive expression group and negative expression group, and the patients were followed up Two groups of patients with different treatment effect and prognosis, to determine their relevance. Results The effective rate of AKT-positive group was lower than that of AKT-negative group, and the poor prognosis rate was higher than that of AKT-negative group. The effective rate of P53 positive expression group was less than that of P53 negative group, and the poor prognosis rate was higher than that of P53 negative group. The effective rate was higher than that of the Her-2 negative expression group, and the proportion of poor prognosis was lower than that of the Her-2 negative expression group (P <0.05). Conclusions The positive expression of AKT and P53 is negatively correlated with the neoadjuvant chemotherapy effect and prognosis in patients with breast cancer. The positive expression rate of Her-2 is positively correlated with the neoadjuvant chemotherapy efficacy and prognosis in patients with breast cancer.